Skip to content
Disclosery

Aquilo Capital Management, LLC

Follow

13F filer, CIK 1591986, SAN FRANCISCO, CA

Aquilo Capital Management, LLC reported $66,317,158 across 15 holdings for the quarter ended 2024-12-31, in a 13F-HR filed 2025-02-14. Its ten largest share positions make up 93.6% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001591986-25-000003

Period
2024-12-31
Reported value
$66.3M
Holdings
15
Top 10 weight
93.6%
New
3
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
PTGXnew+76,592$2.96M
DTILadded+154,573$589K
BCYCadded+40,000$560K
BLUEPRINT MEDICINES CORPadded+5,000$436K
REPARE THERAPEUTICS INCadded+304,351$399K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
MERUS N Vexited-117,855-$5.89M
RGNXreduced-584,406-$4.52M
ARWRreduced-88,224-$1.66M
SUTRO BIOPHARMA INCreduced-762,000-$1.4M
ARVNreduced-60,000-$1.15M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2024

Share positions as resolved from 13F-HR 0001591986-25-000003, largest first. % of portfolio is the value over $58,391,158, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 908,474 shares; 2024Q1: 908,474 shares; 2024Q2: 908,474 shares; 2024Q3: 795,813 shares; 2024Q4: 707,589 shares 707,589$13.3M22.78%-88,224Timeline
BLUEPRINT MEDICINES CORPBLUEPRINT MEDICINES CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 254,827 shares; 2024Q1: 182,151 shares; 2024Q2: 114,600 shares; 2024Q3: 124,600 shares; 2024Q4: 129,600 shares 129,600$11.3M19.36%+5,000
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 881,337 shares; 2024Q1: 388,743 shares; 2024Q2: 328,743 shares; 2024Q3: 208,743 shares; 2024Q4: 183,521 shares 183,521$7.38M12.64%-25,222Timeline
ARVNARVINAS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 489,153 shares; 2024Q1: 405,766 shares; 2024Q2: 428,766 shares; 2024Q3: 388,766 shares; 2024Q4: 328,766 shares 328,766$6.3M10.79%-60,000Timeline
BCYCBICYCLE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 156,692 shares; 2024Q3: 181,911 shares; 2024Q4: 221,911 shares 221,911$3.11M5.32%+40,000Timeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: not reported; 2024Q3: not reported; 2024Q4: 76,592 shares 76,592$2.96M5.06%newTimeline
RGNXREGENXBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 802,424 shares; 2024Q1: 906,248 shares; 2024Q2: 906,248 shares; 2024Q3: 930,708 shares; 2024Q4: 346,302 shares 346,302$2.68M4.58%-584,406Timeline
IMTXIMMATICS N.VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 200,000 shares; 2024Q3: 333,502 shares; 2024Q4: 373,902 shares 373,902$2.66M4.55%+40,400Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 1,043,284 shares; 2024Q1: 574,214 shares; 2024Q2: 500,214 shares; 2024Q3: 317,214 shares; 2024Q4: 367,214 shares 367,214$2.53M4.33%+50,000Timeline
ADICET BIO INCADICET BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 2,531,194 shares; 2024Q3: 2,531,194 shares; 2024Q4: 2,531,194 shares 2,531,194$2.44M4.17%0
DTILPRECISION BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: not reported; 2024Q1: 385,440 shares; 2024Q2: 381,803 shares; 2024Q3: 381,803 shares; 2024Q4: 536,376 shares 536,376$2.04M3.5%+154,573Timeline
REPARE THERAPEUTICS INCREPARE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 633,271 shares; 2024Q1: 633,271 shares; 2024Q2: 956,932 shares; 2024Q3: 989,364 shares; 2024Q4: 1,293,715 shares 1,293,715$1.69M2.9%+304,351
SUTRO BIOPHARMA INCSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 420,649 shares; 2024Q1: 1,165,466 shares; 2024Q2: 762,498 shares; 2024Q3: 762,498 shares; 2024Q4: 498 shares 498$916<0.01%-762,000

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
AMGNAMGEN INC COMcall25,000$6.52Mnew
ARWRARROWHEAD PHARMACEUTICALS IN COMcall75,000$1.41Mnew

Sold out in Q4 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SPYSTATE STR SPDR S&P 500 ETF T75,000$43Mput
MERUS N VMERUS N V117,855$5.89Mshares

How Q4 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001591986-25-000003 base2025-02-14acceptance time not in the bulk data set